Azenta (AZTA) 10-Q 5 Feb 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Dec. 31, 2017	Jan. 26, 2018
Document and Entity Information [Abstract]
Trading Symbol	BRKS
Entity Registrant Name	BROOKS AUTOMATION INC
Entity Central Index Key	933,974
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		70,429,583

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2017	Sep. 30, 2017
Current assets
Cash and cash equivalents	$ 202,339	$ 101,622
Marketable securities	15,658	28
Accounts receivable, net	139,047	120,828
Inventories	115,033	106,395
Prepaid expenses and other current assets	24,782	23,138
Total current assets	496,859	352,011
Property, plant and equipment, net	60,294	58,462
Long-term marketable securities	13,885	2,642
Long-term deferred tax assets	1,642	1,692
Goodwill	272,724	233,638
Intangible assets, net	105,757	83,520
Equity method investment	30,925	28,593
Other assets	5,591	6,070
Total assets	987,677	766,628
Current liabilities
Current portion of long term debt	1,993
Accounts payable	54,242	49,100
Deferred revenue	25,701	24,292
Accrued warranty and retrofit costs	8,218	8,054
Accrued compensation and benefits	16,027	27,065
Accrued restructuring costs	1,127	1,708
Accrued income taxes payable	15,120	11,417
Accrued expenses and other current liabilities	26,977	25,142
Total current liabilities	149,405	146,778
Long-term debt	195,276
Long-term tax reserves	1,412	1,687
Long-term deferred tax liabilities	8,290	3,748
Long-term pension liabilities	1,995	1,979
Other long-term liabilities	5,295	4,792
Total liabilities	361,673	158,984
Commitments and contingencies (Note 16)
Stockholders' Equity
Preferred stock, $0.01 par value- 1,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.01 par value- 125,000,000 shares authorized, 83,891,452 shares issued and 70,429,583 shares outstanding at December 31, 2017, 83,294,848 shares issued and 69,832,979 shares outstanding at September 30, 2017	839	833
Additional paid-in capital	1,879,721	1,874,918
Accumulated other comprehensive income	19,335	15,213
Treasury stock, at cost- 13,461,869 shares	(200,956)	(200,956)
Accumulated deficit	(1,072,935)	(1,082,364)
Total stockholders' equity	626,004	607,644
Total liabilities and stockholders' equity	$ 987,677	$ 766,628

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2017	Sep. 30, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	83,891,452	83,294,848
Common stock, shares outstanding	70,429,583	69,832,979
Treasury stock, shares	13,461,869	13,461,869

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenue
Products	$ 142,184	$ 122,114
Services	47,144	37,841
Total revenue	189,328	159,955
Cost of revenue
Products	84,177	75,679
Services	29,936	27,333
Total cost of revenue	114,113	103,012
Gross profit	75,215	56,943
Operating expenses
Research and development	13,200	10,845
Selling, general and administrative	41,175	31,962
Restructuring charges		975
Total operating expenses	54,375	43,782
Operating income	20,840	13,161
Interest income	149	68
Interest expense	(2,181)	(96)
Gain on settlement of equity method investment		1,847
Other expenses, net	(1,652)	(251)
Income before income taxes and earnings of equity method investment	17,156	14,729
Income tax provision	2,850	2,800
Income before equity in earnings of equity method investment	14,306	11,929
Equity in earnings of equity method investment	2,180	1,942
Net income	$ 16,486	$ 13,871
Basic net income per share (in dollars per share)	$ 0.23	$ 0.20
Diluted net income per share (in dollars per share)	0.23	0.20
Dividend declared per share (in dollars per share)	$ 0.10	$ 0.10
Weighted-average shares used in computing net income per share:
Basic (in shares)	70,183	69,181
Diluted (in shares)	70,864	69,870

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ 16,486	$ 13,871
Other comprehensive income (loss), net of tax:
Cumulative foreign currency translation adjustments	4,131	(10,103)
Unrealized losses on marketable securities, net of tax effects of $0 during each of the three months ended December 31, 2017 and 2016		(11)
Actuarial (losses) gains, net of tax effects of ($2), and $2 during the three months ended December 31, 2017 and 2016	(9)	11
Total other comprehensive income (loss), net of tax	4,122	(10,103)
Comprehensive income	$ 20,608	$ 3,768

CONSOLIDATED STATEMENTS OF COM6

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Statement of Comprehensive Income [Abstract]
Unrealized gains (losses) on marketable securities, tax	$ 0	$ 0
Actuarial (loss) gain, tax	$ (2)	$ 2

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities
Net income	$ 16,486	$ 13,871
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	8,521	6,752
Gain on settlement of equity method investment		(1,847)
Stock-based compensation	4,809	2,498
Amortization of premium on marketable securities and deferred financing costs	122	79
Earnings of equity method investment	(2,180)	(1,942)
Deferred income tax benefit	(689)	(421)
Other gains on disposals of assets		(109)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(16,157)	(11,137)
Inventories	(5,518)	(2,930)
Prepaid expenses and other current assets	3,285	(3,516)
Accounts payable	4,449	13,040
Deferred revenue	1,376	10,737
Accrued warranty and retrofit costs	87	(4)
Accrued compensation and tax withholdings	(11,145)	(6,884)
Accrued restructuring costs	(592)	(2,538)
Accrued expenses and other current liabilities	362	3,061
Net cash provided by operating activities	3,216	18,710
Cash flows from investing activities
Purchases of property, plant and equipment	(2,700)	(3,768)
Purchases of marketable securities	(26,875)
Sales and maturities of marketable securities	100
Acquisitions, net of cash acquired	(65,074)	(5,346)
Purchases of other investments		(170)
Proceeds from sales of property, plant and equipment	200
Net cash used in investing activities	(94,349)	(9,284)
Cash flows from financing activities
Proceeds from term loan	197,554
Payment of deferred financing costs	(318)	(27)
Common stock dividends paid	(7,057)	(6,966)
Net cash provided by (used in) financing activities	190,179	(6,993)
Effects of exchange rate changes on cash and cash equivalents	1,671	(4,574)
Net increase (decrease) in cash and cash equivalents	100,717	(2,141)
Cash and cash equivalents, beginning of period	101,622	85,086
Cash and cash equivalents, end of period	202,339	82,945
Supplemental disclosure of non-cash investing and financing activities:
Capital Expenditures Incurred but Not yet Paid	865	424
Deferred financing costs included in accounts payable	$ 143
Fair value of non-cash consideration for the acquisition of Cool Lab, LLC		$ 10,348

Basis of Presentation

Basis of Presentation	3 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	1. Basis of Presentation The unaudited consolidated financial statements of Brooks Automation, Inc. and its subsidiaries (“Brooks”, or the “Company”) included herein have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, all material adjustments, which are of a normal and recurring nature and necessary for a fair statement of the financial position and results of operations and cash flows for the periods presented, have been reflected in the accompanying unaudited consolidated financial statements. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted and, accordingly, the accompanying financial information should be read in conjunction with the audited consolidated financial statements and notes thereto contained on the Company’s Annual Report on Form 10‑K filed with the United States Securities and Exchange Commission (the “SEC”) for the fiscal year ended September 30, 2017 (the "2017 Annual Report on Form 10‑K"). The accompanying Consolidated Balance Sheet as of September 30, 2017 was derived from the audited annual consolidated financial statements as of the period then ended.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of Estimates The preparation of unaudited consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates are associated with accounts receivable, inventories, goodwill, intangible assets other than goodwill, long-lived assets, derivative financial instruments, deferred income taxes, warranty obligations, revenue recognized using the percentage of completion method, pension obligations and stock-based compensation expense. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances, future projections that management believes to be reasonable under the circumstances. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they occur and become known. Foreign Currency Translation Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Foreign currency exchange losses generated from the settlement and remeasurement of these transactions are recognized in earnings and presented within “Other expenses, net” in the Company’s unaudited Consolidated Statements of Operations. Net foreign currency transaction and remeasurement losses totaled $ 2.0 million and $0.5 million, respectively, during the three months ended December 31, 2017 and 2016. Derivative Instruments The Company has transactions and balances denominated in currencies other than the U.S. dollar. Most of these transactions or balances are denominated in Euros, British Pounds and a variety of Asian currencies. The Company enters into foreign exchange contracts to reduce its exposure to currency fluctuations. The forward contract arrangements that the Company enters into typically mature in three months or less. These transactions do not qualify for hedge accounting. Net gains and losses related to these contracts are recorded as a component of "Other expenses, net" in the accompanying unaudited Consolidated Statements of Operations and are as follows for the three months ended December 31, 2017 and 2016 (in thousands): Three Months Ended December 31, 2017 2016 Realized losses on derivatives not designated as hedging instruments $ (1,673) $ (1,003) The fair values of the forward contracts are recorded in the Company’s accompanying unaudited Consolidated Balance Sheets as "Prepaid expenses and other current assets" and "Accrued expenses and other current liabilities". Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy due to a lack of an active market for these contracts. Fair Value Measurements The Company measures at fair value certain financial assets and liabilities, including cash equivalants and available for sale securities. FASB Accounring Standards Codification (“the ASC”) 820, Fair Value Measurement and Disclosures , establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following levels of inputs may be used to measure fair value: Level 1 Inputs: Quoted prices in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset and liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2 Inputs: Observable inputs other than prices included in Level 1, including quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Inputs: Unobservable inputs that are significant to the fair value of the assets or liabilities and reflect an entity’s own assumptions in pricing assets or liabilities since they are supported by little or no market activity. As of December 31, 2017, the Company had no assets or liabilities measured and recorded at fair value on a recurring basis using Level 3 inputs. Recently Issued Accounting Pronouncements In March 2016, the FASB issued an amendment to the accounting guidance to simplify accounting for share-based payment awards issued to employees. The amendment requires recognition of excess tax benefits or deficiencies within income tax expense or benefit and changes their presentation requirements on the statement of cash flows. Additionally, the entity can make an accounting policy election to either estimate the number of awards that are expected to vest, consistent with the current accounting guidance, or account for forfeitures as they occur. The Company adopted the guidance during the first quarter of fiscal year 2018 on its effective date. Please refer to Note 9, “Income Taxes” and Note 11, “Stock-Based Compensation” and for further discussion. In March 2016, the FASB issued an amendment to the accounting guidance to simplify accounting for embedded derivatives. The amendment clarifies the requirements for assessing whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to the debt host contracts. An entity performing the assessment in accordance with this guidance is required to assess the embedded call (put) options solely in accordance with the four-step decision process set forth in the guidance. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The Company adopted the guidance during the first quarter of fiscal year 2018 which had no impact on its financial position and results of operations. In February 2016, the FASB issued new accounting guidance for reporting lease transactions. In accordance with the provisions of the newly issued guidance, a lessee should recognize at the inception of the arrangement a right-of-use asset and a corresponding lease liability initially measured at the present value of lease payments over the lease term. For finance leases, interest on a lease liability should be recognized separately from the amortization of the right-of-use asset, while for operating leases, total lease costs are recorded on a straight-line basis over the lease term. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying assets to forgo a recognition of right-of-use assets and corresponding lease liabilities and record a lease expense on a straight-line basis. Entities should determine at the inception of the arrangement whether a contract represents a lease or contains a lease which is defined as a right to control the use of identified property for a period of time in exchange for consideration. Additionally, entities should separate the lease components from the non-lease components and allocate the contract consideration on a relative standalone price basis in accordance with provisions of ASC Topic 606, Revenue from Contracts with Customers . The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018 and should be adopted via a modified retrospective approach with certain optional practical expedients that entities may elect to apply. The Company expects to adopt the guidance during the first quarter of fiscal year 2020 and is currently evaluating the impact of this guidance on its financial position and results of operations. In June 2016, the FASB issued new accounting guidance for reporting credit losses. The new guidance introduces a new "expected loss" impairment model that applies to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities and other financial assets. Entities are required to estimate expected credit losses over the life of financial assets and record an allowance against the assets’ amortized cost basis to present them at the amount expected to be collected. Additionally, the guidance amends the impairment model for available for sale debt securities and requires entities to determine whether all or a portion of the unrealized loss on such debt security is a credit loss. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption of the newly issued guidance is permitted for fiscal years, and interim periods within those years, beginning after December 15, 2018. The standard should be applied as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company expects to adopt the guidance during the first quarter of fiscal year 2021 and is currently evaluating the impact of this guidance on its financial position and results of operations. In July 2015, the FASB issued an amendment to the accounting guidance to simplify accounting for inventory. The amendment requires measuring inventory based on the lower of its cost or net realizable value. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The Company adopted the guidance during the first quarter of fiscal year 2018 which did not have a significant impact on its financial position and results of operations. In May 2014, the FASB issued new accounting guidance for reporting revenue recognition. The guidance provides for the recognition of revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. The Company expects to adopt the guidance during the first quarter of fiscal year 2019. The Company has initiated the evaluation of the potential impact of adopting the new guidance on its financial position and results of operations, but has not yet completed such assessment or determined the transition method that will be used to adopt the new guidance. The Company has established an implementation team to analyze its current portfolio of customer contracts and determine the impact of adopting the guidance. The implementation team is also responsible for evaluating and designing the necessary changes to the Company’s business processes, policies, systems and controls to support recognition and disclosure under the new guidance. The Company has established a project plan and substantially completed its preliminary contract assessment. The results of this assessment are currently being analyzed to determine the final impact of adoption on the Company’s operations, consolidated financial statements, and related disclosures. The Company is currently in the process of completing this assessment and quantifying the implications of the new guidance adoption. Based on the preliminary assessment, the Company anticipates that the new guidance will impact the timing of revenue recognition for a portion of its life science revenue which is currently accounted for under a percentage of completion method. The Company may be required to recognize revenue for a portion of these arrangements at the point in time it satisfies performance obligations by transferring control over promised deliverables to the customers in accordance with contractual terms of each arrangement. Additionally, revenue generated from the sale of perpetual or term licenses may be required to be recognized at the point in time control is transferred to customers upon license delivery. Other For further information with regard to the Company’s Significant Accounting Policies, please refer to Note 2 "Summary of Significant Accounting Policies" to the Company’s consolidated financial statements included in the 2017 Annual Report on Form 10‑K.

Marketable Securities

Marketable Securities	3 Months Ended
	Dec. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	3. Marketable Securities The Company invests in marketable securities that are classified as available-for-sale and records them at fair value in the Company’s unaudited Consolidated Balance Sheets. Marketable securities reported as current assets represent investments that mature within one year from the balance sheet date. Long-term marketable securities represent investments with maturity dates greater than one year from the balance sheet date. The securities are valued using matrix pricing and benchmarking and classified within Level 2 of the fair value hierarchy because they are not actively traded. Matrix pricing is a mathematical technique used to value securities by relying on the securities’ relationship to other benchmark quoted prices. The following is a summary of the amortized cost and the fair value, including accrued interest receivable, as well as unrealized holding gains (losses) on the short-term and long-term marketable securities as of December 31, 2017 and September 30, 2017 (in thousands): Gross Gross Amortized Unrealized Unrealized Cost Losses Gains Fair Value December 31, 2017 : U.S. Treasury securities and obligations of U.S. government agencies $ 14,911 $ (10) $ — $ 14,901 Bank certificates of deposits 6,158 — 3 6,161 U.S. corporate securities 4,749 (1) — 4,748 Municipal securities 3,710 (6) — 3,704 Other debt securities 29 — — 29 $ 29,557 $ (17) $ 3 $ 29,543 September 30, 2017 : Corporate securities $ 2,642 $ — $ — $ 2,642 Other debt securities 28 — — 28 $ 2,670 $ — $ — $ 2,670 The fair values of the marketable securities by contractual maturities at December 31, 2017 are presented below (in thousands): Fair Value Due in one year or less $ 15,658 Due after one year through five years 11,148 Due after ten years 2,737 Total marketable securities $ 29,543 Expected maturities could differ from contractual maturities because the security issuers may have the right to prepay obligations without prepayment penalties. The Company reviews the marketable securities for impairment at each reporting period to determine if any of the securities have experienced an other-than-temporary decline in fair value. The Company considers factors, such as the length of time and extent to which the market value has been less than the cost, the financial condition and near-term prospects of the issuer, the Company’s intent to sell, or whether it is more likely than not it will be required to sell the investment before recovery of its amortized cost basis. If the Company believes that an other-than-temporary decline in fair value has occurred, it writes down the investment to its fair value and recognizes the credit loss in earnings and the non-credit loss in accumulated other comprehensive income or loss. As of December 31, 2017, the aggregate fair value of the marketable securities in an unrealized loss position was $20.3 million and was comprised of U.S. Treasury securities and obligations of U.S. government agencies, U.S. corporate securities, municipal securities and bank certificates of deposits. Aggregate unrealized losses for these securities were insignificant as of December 31, 2017 and are presented in the table above. There were no marketable securities in an unrealized loss position as of September 30, 2017. Cash equivalents of $64.2 million and less than $0.1 million, respectively, at December 31, 2017 and September 30, 2017 consist of money market funds and are classified within Level 1 of fair value hierarchy because they are valued using quoted market prices in active markets. Cash equivalents of $9.1 million and less than $0.1 million, respectively at December 31, 2017 and September 30, 2017 consist primarily of U.S. government agency obligations, municipal securities and bank certificates of deposits with original maturities of less than 90 days and are classified within Level 2 of the fair value hierarchy because they are not actively traded.

Acquisitions

Acquisitions	3 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Acquisitions	4. Acquisitions Acquisitions Completed in Fiscal Year 2018 Acquisition of 4titude Limited On October 5, 2017, the Company acquired all of the outstanding capital stock of 4titude Limited (“4titude”), a U.K.-based manufacturer of scientific consumables for biological sample materials used in a variety of genomic and DNA analytical applications. The acquisition of 4titude will expand the Company’s existing offerings of consumables and instruments within the Brooks Life Sciences segment. The aggregate purchase price of $65.2 million, net of cash acquired, consisted primarily of a cash payment of $64.7 million subject to working capital adjustments and the assumption of the seller’s liabilities of $0.5 million. The Company used a market participant approach to record the assets acquired and liabilities assumed in the 4titude acquisition. The purchase price allocation is based on a preliminary valuation and is subject to further adjustments within the measurement period as additional information becomes available related to the fair value of such assets acquired and liabilities assumed. The fair values of inventory, property, plant and equipment, intangible assets, accrued liabilities, tax-related matters and residual goodwill were preliminary as of December 31, 2017. The Company will refine such fair value estimates as new information becomes available during the measurement period. Any adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the acquisition date. The preliminary amounts recorded were as follows (in thousands): Fair Value of Assets and Liabilities Accounts receivable (approximates contractual value) $ 1,581 Inventories 2,667 Prepaid expenses and other current assets 140 Property, plant and equipment 1,555 Intangible assets 27,212 Goodwill 38,033 Accounts payable (286) Accrued liabilities (624) Deferred tax liabilities (5,090) Total purchase price, net of cash acquired $ 65,188 Fair values of intangible assets acquired consisted of customer relationships of $21.4 million, completed technology of $5.2 million, backlog of $0.4 million and trademarks of $0.2 million. The Company used the income approach in accordance with the excess-earnings method to estimate the fair values of customer relationships, backlog and trademarks equal to the present value of the after-tax cash flows attributable to each intangible asset. The Company used the income approach in accordance with the relief-from-royalty method to estimate the fair value of the completed technology which is equal to the present value of the after-tax royalty savings attributable to owning that intangible asset. The weighted average amortization periods for intangible assets acquired are 13 years for completed technology, 10 years for customer relationship intangible assets, 1 year for backlog and 1 year for trademarks. The intangible assets acquired are amortized over the total weighted average period of 10.4 years using methods that approximate the pattern in which the economic benefits are expected to be realized. At the closing of the acquisition of 4titude, a cash payment of $0.4 million was placed into escrow which was ascribed to the purchase price. The escrow was related to potential working capital adjustments and the sellers’ satisfaction of general representations and warranties. The escrow balance was $0.4 million as of December 31, 2017. Goodwill represents the excess of the consideration transferred over the fair value of the net assets acquired and has been assigned to the Brooks Life Sciences segment. Goodwill is primarily the result of expected synergies from combining the operations of 4titude with the Company’s operations and is not deductible for tax purposes. The operating results of 4titude have been reflected in the results of operations for the Brooks Life Sciences segment from the date of the acquisition, which included approximately three months of activity during the first quarter of fiscal year 2018. During the three months ended December 31, 2017, revenue and net loss from 4titude recognized in the Company’s results of operations were $3.4 million and $1.1 million, respectively. During the three months ended December 31, 2017, the net loss included non-recurring charges of $1.2 million related to the step-up in value of the acquired inventories and recurring charges of $1.0 million related to amortization expense of acquired intangible assets. During the three months ended December 31, 2017, the Company incurred $0.5 million in non-recurring transaction costs with respect to the 4titude acquisition which were recorded in "Selling, general and administrative" expenses within the accompanying unaudited Consolidated Statements of Operations. The Company did not present a pro forma information summary for its consolidated results of operations for fiscal year ended September 30, 2017 as if the acquisition of 4titude occurred on October 1, 2016 because such results were immaterial. Acquisitions Completed in Fiscal Year 2017 Acquisition of Pacific Bio-Material Management, Inc. and Novare, LLC On July 5, 2017, the Company entered into an asset purchase agreement with Pacific Bio-Material Management, Inc. (“PBMMI”) and Novare, LLC, a wholly owned subsidiary of PBMMI (collectively, the “sellers”), pursuant to which the Company acquired substantially all of the assets and liabilities of the sellers’ business related to providing storage, transportation, management, and cold chain logistics of biological materials. The Company paid to the sellers cash consideration of $34.3 million, net of cash acquired and subject to working capital adjustments. As of December 31, 2017, the purchase price allocation is based on a preliminary valuation and subject to further adjustments when the Company obtains additional information during the measurement period. At the closing of the acquisition of PBMMI, a cash payment of $3.3 million was placed into escrow which was ascribed to the purchase price. The escrow balance of $3.3 million included $2.9 million related to satisfaction of the sellers' indemnification obligations with respect to their representations and warranties and other indemnities, as well as $0.4 million payable to the former owner of Novare as a compensation for a sale of his ownership interest. This escrow arrangement is administered by the Company on behalf of the sellers. The escrow balances were $2.9 million and $0.3 million, respectively, as of December 31, 2017. The operating results of PBMMI have been reflected in the results of operations for the Brooks Life Sciences segment from the date of the acquisition. During three months ended December 31, 2017, revenue and net loss from PBMMI recognized in the Company’s results of operations were $2.3 million and $0.1 million, respectively. During the three months ended December 31, 2017, the net loss included recurring charges of $0.4 million related to amortization expense of acquired intangible assets. Please refer to Note 3, "Acquisitions" to the Company's consolidated financial statements included in the 2017 Annual Report on Form 10-K for further information on PBMMI acquisition. Acquisition of Cool Lab, LLC On November 28, 2016, the Company acquired 100% of the equity of Cool Lab, LLC ("Cool Lab") from BioCision, LLC ("BioCision"). The Company held a 20% equity ownership interest in BioCision prior to the acquisition. The Company used a market participant approach to record the assets acquired and liabilities assumed in the Cool Lab acquisition. The purchase price allocation were finalized as of December 31, 2017. Please refer to Note 3, “Acquisitions” to the Company’s consolidated financial statements included in the 2017 Annual Report on Form 10-K for further information on this transaction. The Company recorded a liability of $0.7 million in the purchase price allocation that represented a preacquisition contingency incurred on the acquisition date. The obligation is related to a rebate that is due to a particular customer if the annual product sales volume metrics exceed threshold amounts under the provisions of the contract assumed by the Company. Fair value of such liability was determined based on a probability weighted discounted cash flow model. The carrying amount of the liability was $0.8 million and $0.7 million, respectively, at December 31, 2017 and September 30, 2017. The operating results of Cool Lab have been reflected in the results of operations for the Brooks Life Sciences segment from the date of the acquisition, which included approximately one month of activity during the first quarter of fiscal year 2017. During the three months ended December 31, 2017, revenue and net loss from Cool Lab recognized in the Company’s results of operations were $1.0 million and less than $0.1 million, respectively. During the three months ended December 31, 201 6 , revenue and net loss from Cool Lab recognized in the Company’s results of operations were $0.3 million and $0.1 million, respectively. During the three months ended December 31, 2017 and 2016, the net loss included recurring charges of $0.4 million and $0.1 million, respectively, related to amortization expense of acquired intangible assets.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	5. Goodwill and Intangible Assets Goodwill represents the excess of net book value over the estimated fair value of net tangible and identifiable intangible assets of a reporting unit. Goodwill is tested for impairment annually or more often if impairment indicators are present at the reporting unit level. The Company elected April 1 as its annual goodwill impairment assessment date and performs additional impairment tests if triggering events occur. If events occur or circumstances change that would more likely than not reduce fair values of the reporting units below their carrying values, goodwill will be evaluated for impairment between annual tests. No triggering events indicating goodwill impairment occurred during the three months ended December 31, 2017. Please refer to Note 6, "Goodwill and Intangible Assets" to the Company's consolidated financial statements included in the 2017 Annual Report on Form 10-K for further information on the goodwill impairment testing performed during fiscal year 2017. The components of the Company’s goodwill by operating segment at December 31, 2017 and September 30, 2017 are as follows (in thousands): Brooks Semiconductor Solutions Brooks Group Life Sciences Other Total Gross goodwill, at September 30, 2017 $ 655,762 $ 166,820 $ 26,014 $ 848,596 Accumulated goodwill impairments (588,944) — (26,014) (614,958) Goodwill, net of accumulated impairments, at September 30, 2017 66,818 166,820 — 233,638 Acquisitions and adjustments (15) 39,101 — 39,086 Gross goodwill, at December 31, 2017 655,747 205,921 26,014 887,682 Accumulated goodwill impairments (588,944) — (26,014) (614,958) Goodwill, net of accumulated impairments, at December 31, 2017 $ 66,803 $ 205,921 $ — $ 272,724 During the three months ended December 31, 2017, the Company recorded a goodwill increase of $39.1 million primarily related to the acquisition of 4titude which represented the excess of the consideration transferred over the fair value of the net assets acquired. Please refer to the Note 4 "Acquisitions" for further information on this transaction. The components of the Company’s identifiable intangible assets as of December 31, 2017 and September 30, 2017 are as follows (in thousands): December 31, 2017 September 30, 2017 Accumulated Net Book Accumulated Net Book Cost Amortization Value Cost Amortization Value Patents $ 9,028 $ 7,806 $ 1,222 $ 9,028 $ 7,729 $ 1,299 Completed technology 67,032 55,668 11,364 61,662 54,777 6,885 Trademarks and trade names 9,405 5,241 4,164 9,244 4,969 4,275 Customer relationships 152,797 63,790 89,007 130,655 59,594 71,061 $ 238,262 $ 132,505 $ 105,757 $ 210,589 $ 127,069 $ 83,520 Amortization expense for intangible assets was $5.5 million and $4.1 million, respectively, during the three months ended December 31, 2017 and 2016. Estimated future amortization expense for the intangible assets for the remainder of fiscal year 2018 and the subsequent four fiscal years is as follows (in thousands): Fiscal year ended September 30, 2018 $ 16,454 2019 20,810 2020 19,021 2021 13,240 2022 10,553 Thereafter 25,679 $ 105,757

Equity Method Investments

Equity Method Investments	3 Months Ended
	Dec. 31, 2017
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments	6. Equity Method Investments The Company accounts for certain of its investments using the equity method of accounting and records its proportionate share of the investee’s earnings in its results of operations with a corresponding increase in the carrying value of the investment. ULVAC Cryogenics, Inc. The Company and ULVAC Corporation of Chigasaki, Japan each own a 50% stake in the joint venture, ULVAC Cryogenics, Inc (“UCI”). UCI manufactures and sells cryogenic vacuum pumps, principally to ULVAC Corporation. The carrying value of the investment in UCI was $30.9 million and $28.6 million, respectively, at December 31, 2017 and September 30, 2017. During the three months ended December 31, 2017 and 2016, the Company recorded income of $2.2 million and $2.4 million, respectively, representing its proportionate share of UCI’s earnings. Management fee payments received by the Company from UCI were $0.3 million during each of the three months ended December 31, 2017 and 2016.

Line of Credit

Line of Credit	3 Months Ended
	Dec. 31, 2017
Credit Agreement
Line of Credit Facility [Line Items]
Line of Credit	7. Line of Credit The Company maintains a revolving line of credit with Wells Fargo Bank, N.A. and JPMorgan Chase Bank, N.A that provides for revolving credit financing of up to $75 million, subject to borrowing base availability, as defined in the line of credit agreement. The line of credit matures on October 4, 2022 and expires no less than 90 days prior to the term loan expiration. The proceeds from the line of credit are available for permitted acquisitions and general corporate purposes. On October 4, 2017, the Company entered into a $200.0 million Senior Secured Term Loan Facility (the “term loan”) with Morgan Stanley Senior Funding, Inc., JPMorgan Chase Bank, N.A. and Wells Fargo Securities, LLC (collectively, the “lenders”). Coincident with the entry into the term loan agreement, the Company amended certain terms and conditions of the credit agreement and entered into an arrangement with Wells Fargo Bank, N.A. and JPMorgan Chase Bank, N.A. Based on the amended terms of the credit agreement, the line of credit continues to provide for revolving credit financing of up to $75 million, subject to borrowing base availability. Borrowing base availability under the amended line of credit excludes collateral related to fixed assets and is redetermined periodically based on certain percentage of certain eligible U.S. assets, including accounts receivable and inventory. The sublimits for letters of credit were reduced to $7.5 million under the amended terms of the credit agreement. All outstanding borrowings under the credit agreement are guaranteed by the Company and BioStorage Technologies, Inc., its wholly-owned subsidiary (“Guarantor”), and subordinated to the obligations under the term loan which are secured by a first priority lien on substantially all of the assets of the Company and the Guarantor, other than accounts receivable and inventory. Please refer to Note 8, “Debt”, for further information on the term loan transaction . There were no amounts outstanding under the line of credit as of December 31, 2017 and September 30, 2017. The Company records commitment fees and other costs directly associated with obtaining line of credit financing as deferred financing costs which are presented within "Other assets" in the accompanying unaudited Consolidated Balance Sheets. At December 31, 2017 and September 30, 2017, deferred financing costs were $0.6 million and $0.5 million, respectively. Such costs are amortized over the term of the related financing arrangement and are included in “Interest expense” in the accompanying unaudited Consolidated Statements of Operations. The line of credit contains certain customary representations and warranties, a financial covenant, affirmative and negative covenants, as well as events of default. The Company was in compliance with the line of credit covenants as of December 31, 2017 and September 30, 2017.

Debt

Debt	3 Months Ended
	Dec. 31, 2017
Senior Secured Term Loan Facility
Debt Instrument [Line Items]
Debt	8. Debt On October 4, 2017, the Company entered into a $200.0 million term loan with the lenders. The term loan was issued at $197.6 million, or 98.8% of its par value, resulting in a discount of $2.4 million, or 1.2%, which represented loan origination fees paid at the closing. The Company incurred additional deferred financing costs of $0.4 million during the three months ended December 31, 2017. The loan proceeds are be used for general corporate purposes, including acquisitions. The loan principal amount may be increased by an aggregate amount equal to $75.0 million plus any voluntary repayments of the term loans plus an amount such that the secured leverage ratio of the Company is less than 3.00 to 1.00. Under the terms of the loan agreement, the Company may elect for the loan to bear an interest rate as Eurodollar Borrowings or as Alternate Base Rate, or ABR Borrowings. Interest applicable to Eurodollar Borrowings is based on the Adjusted LIBO Rate plus applicable margin of 2.50%. The Adjusted LIBO Rate is the rate appearing on Bloomberg screen LIBOR01 which gets reset at the beginning of each selected interest period based on LIBOR rate then in effect. Interest applicable to Alternate Base Rate Borrowings is based on the Alternate Base Rate plus applicable margin of 1.50%. Alternate Base Rate is determined based on the highest of: (a) the federal funds effective rate plus 0.50%, (b) prime rate plus 1.00%, or (c) one-month LIBOR rate plus 1.00%. The Company’s obligations under the term loan are guaranteed by the Company’s wholly-owned subsidiary, BioStorage Technologies, Inc. (the “guarantor”), subject to the terms and conditions of the term loan agreement. The Company and the guarantor granted the lenders a perfected first priority security interest in substantially all of the assets of the Company and the guarantor to secure the repayment of the term loan. The term loan matures and becomes fully payable on October 4, 2024. The principal is payable in installments equal to 0.25% of the initial principal amount of the term loans on March 31 st , June 30 th , September 30 th and December 31 st of each year, with any remaining amount of principal becoming due and payable on the maturity date. The Company is required to begin making principal payments commencing with the second quarter of fiscal year 2018. All accrued and unpaid interest on ABR Borrowings shall be due and payable at the same time as the loan principal installments. All accrued and unpaid interest on Eurodollar Borrowings shall be due on the last day of each interest period elected by the Company for such Eurodollar Borrowings, except for interest periods of more than three months in which case all accrued and unpaid interest shall be due and payable every three months. Subject to certain conditions stated in the term loan agreement, the Company may redeem the term loan at any time at its option without a significant premium or penalty, except for a repricing transaction, as defined in the term loan agreement, which is subject to a premium of 1.00% of the loan principal amount during the first six months of the loan term . The Company would be required to redeem the term loan at the principal amount then outstanding upon occurrence of certain events, including (i) net proceeds received from the sale or other disposition of the Company’s or guarantor’ assets, subject to certain limitations, (ii) casualty and condemnation proceeds received by the Company or the guarantor, subject to certain exceptions, (iii) net proceeds received by the Company or the guarantor from the issuance of debt or disqualified capital stock after October 4, 2017. Commencing on December 31, 2018, the Company will be required to make principal payments equal to the excess cash flow amount, as defined in the term loan agreement. Such prepayments are equal to 50% of the preceding year excess cash flow amount reduced by voluntary prepayments of the term loan, subject to certain limitations. The Company records commitment fees and other costs directly associated with obtaining term loan financing as deferred financing costs which are presented as a reduction of the term loan principal balance in the accompanying unaudited Consolidated Balance Sheets. Such costs are accreted over the term of the loan using the effective interest rate method and are included in “Interest expense” in the accompanying unaudited Consolidated Statements of Operations. At December 31, 2017, deferred financing costs were $2.7 million. During the three months ended December 31, 2017, the weighted average stated interest rate paid on the term loan was 4%. During the three months ended December 31, 2017, the Company incurred aggregate interest expense of $2.1 million in connection with the term loan borrowings, which included $0.1 million of deferred financing costs amortization. The term loan agreement contains certain customary representations and warranties, covenants and events of default. If any of the events of default occur and are not waived or cured within applicable grace periods, any unpaid amounts under the term loan agreement will bear an annual interest rate at 2.00% above the rate otherwise applicable under the terms and conditions of such agreement. The term loan agreement does not contain financial maintenance covenants. As of December 31, 2017, the Company was in compliance with all covenants and conditions under the term loan agreement. The following are the future minimum principal payment obligations under the term loan as of December 31, 2017: Amount Fiscal year ended September 30, 2018 $ 1,496 2019 1,978 2020 1,958 2021 1,938 2022 1,919 Thereafter 190,711 Total outstanding principal balance 200,000 Unamortized deferred financing costs (2,731) 197,269 Term loan, current portion 1,993 Term loan, long-term portion $ 195,276 As of December 31, 2017, estimated fair value of the term loan outstanding principal balance approximates its carrying value. The fair value was determined based on observable market inputs and classified within Level 2 of fair value hierarchy due to a lack of an active market for this term loan or a similar loan instrument.

Income Taxes

Income Taxes	3 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	9 . Income Taxes The Company recorded an income tax provision of $ 2.9 million and $2.8 million, respectively, during the three months ended December 31, 2017 and 2016. The tax provision for the three months ended December 31, 2017 was primarily driven by the foreign income generated during the quarter. This provision is partially offset by $0.3 million of tax benefits related to the reduction of reserves for unrecognized tax benefits and $0.7 million of tax benefits related to the re-measurement of net U.S. deferred tax liabilities at the reduced 21 percent federal income tax rate. The income tax provision for the three months ended December 31, 2016 was primarily driven by foreign income generated during the quarter, partially offset by $0.7 million of tax benefits related to the reduction of reserves for unrecognized tax benefits. During the first quarter of fiscal year 2018, the Company adopted the Accounting Standard Update (“ASU”) 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting . Upon adoption of ASU 2016-09, the Company amends the accounting for employee share-based payment transactions to recognize tax effects resulting from the settlement of stock-based awards as income tax expense or benefit in the income statement in the reporting period in which they occur. Adoption of this ASU required recognition of a cumulative effect adjustment to retained earnings in connection with the establishment of a deferred tax asset for any prior year net excess tax benefits or tax deficiencies not previously recorded. This adjustment resulted in a $4.0 million increase to retained earnings and deferred tax asset for net prior year excess tax benefits, with a corresponding decrease to retained earnings for the establishment of valuation allowance against the deferred tax asset. During the three months ended December 31, 2017 this change had no impact to our income statement or tax rate as a result of the full valuation allowance which exists against U.S. deferred tax assets. During the three months ended December 31, 2017, the Tax Cuts and Jobs Act (“Tax Reform”) was enacted in the U.S., making significant tax law changes affecting the Company. The SEC has issued Staff Accounting Bulletin 118 (“SAB 118”), which has provided guidance for companies that have not completed the accounting for the income tax effects of Tax Reform. Under SAB 118, a company may report provisional amounts based on reasonable estimates where the accounting is incomplete. These amounts are subject to adjustments during a measurement period of up to one year beginning in the reporting period of the enactment date. Upon the enactment of Tax Reform, the Company is subject to a toll charge in the U.S. on its previously untaxed accumulated foreign earnings. The toll charge is treated as an inclusion of the company’s accumulated foreign earnings in U.S. taxable income during the tax year ended September 30, 2018. Any taxes due associated with the toll charge will be payable over an eight year period. The Company has estimated that its accumulated foreign earnings are $120 million which is a provisional amount subject to the measurement period described in Staff Accounting Bulletin 118. There are still incomplete components related to the accumulated foreign earnings calculations for older tax years that require additional time to complete the calculations. The Company also has a history of foreign mergers and acquisitions and proper determination of the impact on the accumulated earnings is complex. The Company has not recorded any provision for currently estimated tax inclusion associated with the toll charge as sufficient previously un-benefited tax attributes, with valuation allowances, exist to offset the inclusion income or resulting tax. As a result of Tax Reform, the Company calculated its U.S. tax provision for the three months ended December 31, 2017 using a blended U.S. statutory tax rate of 24.5% which is a prorated allocation of the 35% rate which was in effect prior to tax reform through December 31, 2017 and the 21% rate which will be in effect for the remainder of the fiscal year. The Company recorded a discrete benefit of $0.7 million in the three months ended December 31, 2017 due to the impact of the U.S. rate change on its net U.S. deferred tax liabilities. As of December 31, 2017, the Company maintains its indefinite reinvestment assertion on foreign earnings until the Company can complete its assessment of Tax Reform impacts on reinvestment plans, which will continue to be evaluated during the measurement period described in SAB 118. While the toll charge is a forced deemed repatriation of foreign earnings and an inclusion in U.S. taxable income, there are still additional costs of repatriating the foreign earnings such as foreign withholding taxes and state taxes. The Company evaluates the realizability of its deferred tax assets by tax-paying component and assesses the need for a valuation allowance on a quarterly basis. The Company evaluates the profitability of each tax-paying component on a historic cumulative basis and on a forward looking basis in the course of performing this analysis. As described below, the Company’s evaluation of all positive and negative evidence and corresponding conclusion regarding maintaining a valuation allowance at December 31, 2017 in the U.S. will be a part of its assessment during the measurement period under SAB 118 of the future impacts Tax Reform will have on its positive and negative evidence to support the reversal of all or some portion of these allowances. Please refer to Note 10, "Income Taxes" to the Company’s consolidated financial statements included in the 2017 Annual Report on Form 10-K for further information on the valuation allowance. As previously described, the Company maintains a full valuation allowance on its U.S. deferred tax assets. During the three months ended December 31, 2017, the Company considered the impacts of Tax Reform that will be immediately effective and those that will be effective for future years. In consideration of the effects of Tax Reform, the Company is still in the process of fully evaluating, during the measurement period under SAB 118, all future impacts of the changes as they relate to the need for the U.S. valuation allowance. The final determination of the various impacts of Tax Reform could have a significant impact to U.S. tax obligations, and could require the Company to change its U.S. valuation allowance conclusion in a future period. As of the time of this filing, the Company believes a full valuation allowance on its U.S. deferred tax assets is required until a full analysis of the impact of Tax Reform is finalized. The Company is subject to U.S. federal income tax and various state, local and international income taxes in various jurisdictions. The amount of income taxes paid is subject to the Company’s interpretation of applicable tax laws in the jurisdictions in which it files tax returns. In the normal course of business, the Company is subject to income tax audits in various global jurisdictions in which it operates. The years subject to examination vary for the U.S. and international jurisdictions, with the earliest tax year being 2011. Based on the outcome of these examinations or the expiration of statutes of limitations for specific jurisdictions, it is reasonably possible that the related unrecognized tax benefits could change from those recorded in the Company’s unaudited Consolidated Balance Sheets. The Company currently anticipates that it is reasonably possible that the unrecognized tax benefits will be reduced by approximately $0.2 million within the next twelve months.

Other Balance Sheet Information

Other Balance Sheet Information	3 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Balance Sheet Information	10. Other Balance Sheet Information The following is a summary of accounts receivable at December 31, 2017 and September 30, 201 7 (in thousands): December 31, September 30, 2017 2017 Accounts receivable $ 140,490 $ 122,868 Less allowance for doubtful accounts (1,384) (1,959) Less allowance for sales returns (59) (81) Accounts receivable, net $ 139,047 $ 120,828 The following is a summary of inventories at December 31, 2017 and September 30, 2017 (in thousands): December 31, September 30, 2017 2017 Inventories Raw materials and purchased parts $ 76,389 $ 73,819 Work-in-process 11,729 10,548 Finished goods 26,915 22,028 Total inventories $ 115,033 $ 106,395 Reserves for excess and obsolete inventory were $22.9 million and $23.5 million, respectively, at December 31, 2017 and September 30, 2017. During the three months ended December 31, 2017 and the fiscal year ended September 30, 201 7 , the Company had cumulative capitalized direct costs of $5.0 million and $4.7 million, respectively, associated with the development of software for its internal use which are included within "Property, plant and equipment, net" in the accompanying unaudited Consolidated Balance Sheets. During the three months ended December 31, 2017, the Company capitalized direct costs of $0.3 million associated with development of software for its internal use. The Company establishes reserves for estimated costs of product warranties based on historical information. Product warranty reserves are recorded at the time product revenue is recognized, and retrofit accruals are recorded at the time retrofit programs are established. The Company’s warranty obligation is affected by product failure rates, utilization levels, material usage, service delivery costs incurred in correcting a product failure and supplier warranties on parts delivered to the Company. The following is a summary of product warranty and retrofit activity on a gross basis for the three months ended December 31, 2017 and 2016 (in thousands): Activity -Three Months Ended December 31, 2017 Balance Balance September 30, December 31, 2017 Accruals Costs Incurred 2017 $ 8,054 $ 2,336 $ (2,172) $ 8,218 Activity -Three Months Ended December 31, 2016 Balance Balance September 30, December 31, 2016 Accruals Costs Incurred 2016 $ 6,324 $ 2,507 $ (2,614) $ 6,217

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	11. Stock-Based Compensation The Company may issue restricted stock units and restricted stock awards (collectively "restricted stock units") and stock options which vest upon the satisfaction of a performance condition and/or a service condition. In addition, the Company issues shares to participating employees pursuant to an employee stock purchase plan and unrestricted stock awards to its directors in accordance with its director compensation program. The following table reflects stock-based compensation expense recorded during the three months ended December 31, 2017 and 2016 (in thousands): Three Months Ended December 31, 2017 2016 Restricted stock $ 4,602 $ 2,365 Employee stock purchase plan 207 133 Total stock-based compensation expense $ 4,809 $ 2,498 The fair value of restricted stock units is determined based on the number of shares granted and the closing price of the Company’s common stock quoted on the Nasdaq Stock Market on the date of grant. The Company recognizes stock-based compensation expense on a straight-line basis, net of estimated forfeitures, over the requisite service period. Additionally, the Company assesses the likelihood of achieving the performance goals against previously established performance targets in accordance with the Company’s long-term equity incentive plan for stock-based awards that vest upon or after the satisfaction of these goals. During the first quarter of fiscal year 2018, the Company adopted the Accounting Standard Update (“ASU”) 2016-09, “ Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting .” Upon adoption of ASU 2016-09, the Company made an accounting policy election to continue accounting for forfeitures by applying an estimated forfeiture rate. The adoption of ASU 2016-09 did not have an impact on the stock compensation expense amount recognized during the three months ended December 31, 2017 and accumulated deficit at December 31, 2017. The Company grants restricted stock units that vest over a required service period and/or achievement of certain operating performance goals. Restricted stock units granted with performance goals may also have a required service period following the achievement of all or a portion of the goals. The following table reflects restricted stock units granted during the three months ended December 31, 2017 and 2016: Time-Based Performance- Total Units Units Stock Grants Based Units Three months ended December 31, 2017 471,151 190,266 546 Three months ended December 31, 2016 951,266 362,113 815 Time-Based Grants Restricted stock units granted with a required service period typically have three year vesting schedules in which one-third of awards vest at the first anniversary of the grant date, one-third vest at the second anniversary of the grant date and one-third vest at the third anniversary of the grant date, subject to the award holders meeting service requirements. Stock Grants During the three months ended December 31, 2017 and 2016, the Company granted and issued 546 and 815 units, respectively, to the members of the Company’s Board of Directors which were related to deferred quarterly dividends. The value of the units granted was equal to the value of cash dividends that would be paid on the number of deferred shares based on the closing price of the Company’s stock on the dividend record date. Such units vested upon their issuance, but receipt of the Company shares is deferred until the holders attain a certain age or cease to provide services to the Company as Board members. There were no annual awards of unrestricted shares of the Company stock and compensation-related restricted stock units granted to the members of the Company's Board of Directors during the three months ended December 31, 2017 and 2016, respectively. Performance-Based Grants Performance-based restricted stock units are earned based on the achievement of performance criteria established by the Human Resources and Compensation Committee of the Board of Directors. The criteria for performance-based awards are weighted and have threshold, target and maximum performance goals. Performance-based awards granted in fiscal year 2017 allow participants to earn 100% of a targeted number of restricted stock units if the Company’s performance meets its target for each applicable financial metric, and up to a maximum of 200% of the restricted stock units target if the Company’s performance for such metrics meets the maximum threshold. Performance below the minimum threshold for each financial metric results in award forfeitures. Performance goals will be measured over a three year period at the end of fiscal year 2020 to determine the number of units earned by recipients who continue to meet a service requirement. Units held by recipients who fail to meet the continued service requirement are forfeited. Earned units for recipients who continue to meet the service requirements vest on the date the Company’s Board of Directors determines the number of units earned, which will be approximately the third anniversary of the grant date. Performance-based awards granted in fiscal year 2016 also include provisions that allow participants to earn threshold, target and maximum awards ranging from 0% of the award for performance below the minimum threshold, 100% of the award for performance at target, and up to a maximum of 200% of the award if the Company achieves the maximum performance goals. Restricted Stock Unit Activity The following table summarizes restricted stock unit activity for the three months ended December 31, 2017: Weighted Average Grant-Date Shares Fair Value Outstanding at September 30, 2017 2,474,011 $ 12.34 Granted 471,151 34.25 Vested (586,352) 12.42 Forfeited (14,737) 16.48 Outstanding at December 31, 2017 2,344,073 $ 16.75 The weighted average grant date fair value of res tricted stock units granted during the three months ended December 31, 2017 and 2016 was $34.25 and $13.93, respectively. The fair value of restricted stock units vested during the three months ended December 31, 2017 and 2016 was $19.0 million and $11.3 million, respectively. During the three months ended December 31, 2017 and 2016, the Company remitted $6. 3 million and $3.8 million, respectively, for withholding taxes on vested restricted stock units, of which $0.1 million was paid by the Company during the three months ended December 31, 2016. There were no taxes on vested restricted stock units paid by the Company during the three months ended December 31, 2017. During the three months ended December 31, 2017 and 2016, the Company received $6. 3 million and $3.7 million, respectively, in cash proceeds from employees to satisfy their tax obligations as a result of share issuances. As of December 31, 2017, the unrecognized compensation cost related to restricted stock units that are expected to vest is $33.2 million and will be recognized over an estimated weighted average service period of approximately 1. 9 years. Employee Stock Purchase Plan The Company maintains an Employee Stock Purchase Plan that allows its employees to purchase shares of common stock at a price equal to 85% of the fair market value of the Company’s stock at the beginning or the end of the semi-annual period, whichever is lower. There were no shares purchased by employees or issued by the Company under the employee stock purchase plan during the three months ended December 31, 2017 and 2016.

Earnings per Share

Earnings per Share	3 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Earnings per Share	12. Earnings per Share The calculations of basic and diluted net income per share and basic and diluted weighted average shares outstanding are as follows for the three months ended December 31, 2017 and 2016 (in thousands, except per share data): Three Months Ended December 31, 2017 2016 Net income $ 16,486 $ 13,871 Weighted average common shares outstanding used in computing basic earnings per share 70,183 69,181 Dilutive common stock options and restricted stock units 681 689 Weighted average common shares outstanding used in computing diluted earnings per share 70,864 69,870 Basic net income per share $ 0.23 $ Diluted net income per share $ 0.23 $ During the three months ended December 31, 2017, 190,000 antidilutive restricted stock units were excluded from the computation of diluted earnings per share based on the treasury stock method. There were no such awards during the three months ended December 31, 2016.

Restructuring Charges

Restructuring Charges	3 Months Ended
	Dec. 31, 2017
Restructuring and Related Activities [Abstract]
Restructuring Charges	13. Restructuring Charges There were no restructuring charges recorded by the Company during the three months ended December 31, 2017. During the three months ended December 31, 2016, the Company recorded restructuring charges of $1.0 million related to severance. Such charges were comprised of: (i) $0.7 million of costs related to the Company-wide restructuring action, (ii) $0.2 million of costs attributable to the Brooks Semiconductor Solutions Group segment related to the integration of Contact Co., Ltd. after its acquisition by the Company, and (iii) $0.1 million of costs attributable to the Brooks Life Sciences segment related to streamlining the segment's management structure, integrating acquisitions and improving profitability. The following is a summary of activity related to the Company’s restructuring charges for the three months ended December 31, 2017 and 2016 (in thousands): Activity -Three Months Ended December 31, 2017 Balance Balance September 30, December 31, 2017 Expenses Payments 2017 Total restructuring liabilities related to workforce termination benefits $ 1,708 $ — $ (581) $ 1,127 Activity -Three Months Ended December 31, 2016 Balance Balance September 30, December 31, 2016 Expenses Payments 2016 Total restructuring liabilities related to workforce termination benefits $ 5,939 $ 975 $ (3,687) $ 3,227 As of December 31, 2017, accrued restructuring costs of $1.1 million were primarily attributable to the restructuring actions within the Brooks Semiconductor Solutions Group segment and comprised primarily of $0.8 million related to the consolidation of the Jena, Germany repair facility and $0.2 million related to streamlining field service operations. Accrued restructuring costs are expected to be paid within the next twelve months. Please refer to Note 15, “Restructuring and Other Charges” to the Company’s consolidated financial statements included in the 2017 Annual Report on Form 10-K for further information on the restructuring actions discussed above.

Segment Information

Segment Information	3 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Segment Information	14. Segment Information Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company’s Chief Executive Officer is the Company’s chief operating decision maker. The Company reports its financial results for two operating and reportable segments which consist of Brooks Semiconductor Solutions Group segment and Brooks Life Sciences segment. Please refer to Note 18, "Segment and Geographic Information" to the Company’s consolidated financial statements included in the 201 7 Annual Report on Form 10‑K for further information on the operating segments’ description and accounting policies. The following is the summary of the financial information for the Company’s operating and reportable segments for the three months ended December 31, 2017 and 2016 (in thousands): Brooks Semiconductor Brooks Solutions Group Life Sciences Total Three Months Ended December 31, 2017: Revenue Products $ 120,203 $ 21,981 $ 142,184 Services 21,683 25,461 47,144 Segment revenue $ 141,886 $ 47,442 $ 189,328 Gross profit $ 59,453 $ 15,762 $ 75,215 Segment operating income (loss) 26,362 (140) 26,222 Depreciation expense 1,149 1,549 2,698 Three Months Ended December 31, 2016: Revenue Products $ 109,395 $ 12,719 $ 122,114 Services 17,221 20,620 37,841 Segment revenue $ 126,616 $ 33,339 $ 159,955 Gross profit $ 45,468 $ 11,475 $ 56,943 Segment operating income (loss) 17,371 112 17,483 Depreciation expense 1,275 1,090 2,365 Assets: December 31, 2017 $ 340,367 $ 382,884 $ 723,251 September 30, 2017 325,408 306,666 632,074 The following is a reconciliation of the Company’s operating and reportable segments’ operating income and segment assets to the corresponding amounts presented in the accompanying unaudited Consolidated Balance Sheets and Consolidated Statements of Operations for the three months ended December 31, 2017 and 2016 (in thousands): Three Months Ended December 31, 2017 2016 Segment operating income $ 26,222 $ 17,483 Amortization of acquired intangible assets 4,589 3,064 Restructuring charges — 975 Other unallocated corporate expenses 793 283 Total operating income $ 20,840 $ 13,161 December 31, September 30, 2017 2017 Segment assets $ 723,251 $ 632,074 Cash, cash equivalents and marketable securities 231,882 104,292 Deferred tax assets 1,642 1,692 Equity method investments 30,902 28,570 Total assets $ 987,677 $ 766,628

Significant Customers

Significant Customers	3 Months Ended
	Dec. 31, 2017
Risks and Uncertainties [Abstract]
Significant Customers	15. Significant Customers The Company had one customer within the Brooks Semiconductor Solutions Group segment that accounted for 10% or more of its consolidated revenue, at 11%, during each of the three months ended December 31, 2017 and 2016 . As of December 31, 2017 and September 30, 2017, the Company had no customers that accounted for 10% or more of the Company’s total receivables. For purposes of determining the percentage of revenue generated from any of the Company’s original equipment manufacturer (the "OEM") customers, the Company does not include revenue from products sold to contract manufacturer customers who in turn sell to the OEMs. If the Company included revenue from products sold to contract manufacturer customers supporting the Company’s OEM customers, the percentage of the Company’s total revenue derived from certain OEM customers would be higher.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Letters of Credit At each of December 31, 2017 and September 30, 2017, the Company had approximately $3.5 million of letters of credit outstanding related primarily to customer advances and other performance obligations. These arrangements guarantee the refund of advance payments received from our customers in the event that the product is not delivered or warranty obligations are not fulfilled in accordance with the contract terms. These obligations could be called by the beneficiaries at any time before the expiration date of the particular letter of credit if the Company fails to meet certain contractual requirements. None of these obligations were called during the three months ended December 31, 2017 and the fiscal year ended September 30, 2017, and the Company currently does not anticipate any of these obligations to be called in the near future. Purchase Commitments The Company has non-cancellable contracts and purchase orders for inventory of $128.6 million and $122.0 million, respectively, at December 31, 2017 and September 30, 2017. The Company is subject to various legal proceedings, both asserted and unasserted, that arise in the ordinary course of business. The Company cannot predict the ultimate outcome of such legal proceedings or in certain instances provide reasonable ranges of potential losses. However, as of the date of this report, the Company believes that none of these claims will have a material adverse effect on its consolidated financial position or results of operations. In the event of unexpected subsequent developments and given the inherent unpredictability of these legal proceedings, there can be no assurance that the Company’s assessment of any claim will reflect the ultimate outcome, and an adverse outcome in certain matters could, from time to time, have a material adverse effect on the Company’s consolidated financial position or results of operations in particular quarterly or annual periods.

Subsequent Events

Subsequent Events	3 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events Dividend On January 31, 2018, the Company’s Board of Directors declared a cash dividend of $0.10 per share payable on March 23, 201 8 to common stockholders of record as of March 2, 201 8 . Dividends are declared at the discretion of the Company’s Board of Directors and depend on the Company’s actual cash flows from operations, its financial condition and capital requirements and any other factors the Company’s Board of Directors may consider relevant. Future dividend declarations, as well as the record and payment dates for such dividends, will be determined by the Company’s Board of Directors on a quarterly basis.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of unaudited consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates are associated with accounts receivable, inventories, goodwill, intangible assets other than goodwill, long-lived assets, derivative financial instruments, deferred income taxes, warranty obligations, revenue recognized using the percentage of completion method, pension obligations and stock-based compensation expense. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances, future projections that management believes to be reasonable under the circumstances. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they occur and become known.
Foreign Currency Translation	Foreign Currency Translation Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Foreign currency exchange losses generated from the settlement and remeasurement of these transactions are recognized in earnings and presented within “Other expenses, net” in the Company’s unaudited Consolidated Statements of Operations. Net foreign currency transaction and remeasurement losses totaled $ 2.0 million and $0.5 million, respectively, during the three months ended December 31, 2017 and 2016.
Derivative Financial Instruments	Derivative Instruments The Company has transactions and balances denominated in currencies other than the U.S. dollar. Most of these transactions or balances are denominated in Euros, British Pounds and a variety of Asian currencies. The Company enters into foreign exchange contracts to reduce its exposure to currency fluctuations. The forward contract arrangements that the Company enters into typically mature in three months or less. These transactions do not qualify for hedge accounting. Net gains and losses related to these contracts are recorded as a component of "Other expenses, net" in the accompanying unaudited Consolidated Statements of Operations and are as follows for the three months ended December 31, 2017 and 2016 (in thousands): Three Months Ended December 31, 2017 2016 Realized losses on derivatives not designated as hedging instruments $ (1,673) $ (1,003) The fair values of the forward contracts are recorded in the Company’s accompanying unaudited Consolidated Balance Sheets as "Prepaid expenses and other current assets" and "Accrued expenses and other current liabilities". Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy due to a lack of an active market for these contracts.
Fair Value Measurements	Fair Value Measurements The Company measures at fair value certain financial assets and liabilities, including cash equivalants and available for sale securities. FASB Accounring Standards Codification (“the ASC”) 820, Fair Value Measurement and Disclosures , establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following levels of inputs may be used to measure fair value: Level 1 Inputs: Quoted prices in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset and liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2 Inputs: Observable inputs other than prices included in Level 1, including quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Inputs: Unobservable inputs that are significant to the fair value of the assets or liabilities and reflect an entity’s own assumptions in pricing assets or liabilities since they are supported by little or no market activity. As of December 31, 2017, the Company had no assets or liabilities measured and recorded at fair value on a recurring basis using Level 3 inputs.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In March 2016, the FASB issued an amendment to the accounting guidance to simplify accounting for share-based payment awards issued to employees. The amendment requires recognition of excess tax benefits or deficiencies within income tax expense or benefit and changes their presentation requirements on the statement of cash flows. Additionally, the entity can make an accounting policy election to either estimate the number of awards that are expected to vest, consistent with the current accounting guidance, or account for forfeitures as they occur. The Company adopted the guidance during the first quarter of fiscal year 2018 on its effective date. Please refer to Note 9, “Income Taxes” and Note 11, “Stock-Based Compensation” and for further discussion. In March 2016, the FASB issued an amendment to the accounting guidance to simplify accounting for embedded derivatives. The amendment clarifies the requirements for assessing whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to the debt host contracts. An entity performing the assessment in accordance with this guidance is required to assess the embedded call (put) options solely in accordance with the four-step decision process set forth in the guidance. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The Company adopted the guidance during the first quarter of fiscal year 2018 which had no impact on its financial position and results of operations. In February 2016, the FASB issued new accounting guidance for reporting lease transactions. In accordance with the provisions of the newly issued guidance, a lessee should recognize at the inception of the arrangement a right-of-use asset and a corresponding lease liability initially measured at the present value of lease payments over the lease term. For finance leases, interest on a lease liability should be recognized separately from the amortization of the right-of-use asset, while for operating leases, total lease costs are recorded on a straight-line basis over the lease term. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying assets to forgo a recognition of right-of-use assets and corresponding lease liabilities and record a lease expense on a straight-line basis. Entities should determine at the inception of the arrangement whether a contract represents a lease or contains a lease which is defined as a right to control the use of identified property for a period of time in exchange for consideration. Additionally, entities should separate the lease components from the non-lease components and allocate the contract consideration on a relative standalone price basis in accordance with provisions of ASC Topic 606, Revenue from Contracts with Customers . The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018 and should be adopted via a modified retrospective approach with certain optional practical expedients that entities may elect to apply. The Company expects to adopt the guidance during the first quarter of fiscal year 2020 and is currently evaluating the impact of this guidance on its financial position and results of operations. In June 2016, the FASB issued new accounting guidance for reporting credit losses. The new guidance introduces a new "expected loss" impairment model that applies to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities and other financial assets. Entities are required to estimate expected credit losses over the life of financial assets and record an allowance against the assets’ amortized cost basis to present them at the amount expected to be collected. Additionally, the guidance amends the impairment model for available for sale debt securities and requires entities to determine whether all or a portion of the unrealized loss on such debt security is a credit loss. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption of the newly issued guidance is permitted for fiscal years, and interim periods within those years, beginning after December 15, 2018. The standard should be applied as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company expects to adopt the guidance during the first quarter of fiscal year 2021 and is currently evaluating the impact of this guidance on its financial position and results of operations. In July 2015, the FASB issued an amendment to the accounting guidance to simplify accounting for inventory. The amendment requires measuring inventory based on the lower of its cost or net realizable value. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The Company adopted the guidance during the first quarter of fiscal year 2018 which did not have a significant impact on its financial position and results of operations. In May 2014, the FASB issued new accounting guidance for reporting revenue recognition. The guidance provides for the recognition of revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. The Company expects to adopt the guidance during the first quarter of fiscal year 2019. The Company has initiated the evaluation of the potential impact of adopting the new guidance on its financial position and results of operations, but has not yet completed such assessment or determined the transition method that will be used to adopt the new guidance. The Company has established an implementation team to analyze its current portfolio of customer contracts and determine the impact of adopting the guidance. The implementation team is also responsible for evaluating and designing the necessary changes to the Company’s business processes, policies, systems and controls to support recognition and disclosure under the new guidance. The Company has established a project plan and substantially completed its preliminary contract assessment. The results of this assessment are currently being analyzed to determine the final impact of adoption on the Company’s operations, consolidated financial statements, and related disclosures. The Company is currently in the process of completing this assessment and quantifying the implications of the new guidance adoption. Based on the preliminary assessment, the Company anticipates that the new guidance will impact the timing of revenue recognition for a portion of its life science revenue which is currently accounted for under a percentage of completion method. The Company may be required to recognize revenue for a portion of these arrangements at the point in time it satisfies performance obligations by transferring control over promised deliverables to the customers in accordance with contractual terms of each arrangement. Additionally, revenue generated from the sale of perpetual or term licenses may be required to be recognized at the point in time control is transferred to customers upon license delivery.

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of Net Gains and Losses Realized on Derivative Instruments	Net gains and losses related to these contracts are recorded as a component of "Other expenses, net" in the accompanying unaudited Consolidated Statements of Operations and are as follows for the three months ended December 31, 2017 and 2016 (in thousands): Three Months Ended December 31, 2017 2016 Realized losses on derivatives not designated as hedging instruments $ (1,673) $ (1,003)

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Dec. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Summary of Marketable Securities Including Accrued Interest Receivable	The following is a summary of the amortized cost and the fair value, including accrued interest receivable, as well as unrealized holding gains (losses) on the short-term and long-term marketable securities as of December 31, 2017 and September 30, 2017 (in thousands): Gross Gross Amortized Unrealized Unrealized Cost Losses Gains Fair Value December 31, 2017 : U.S. Treasury securities and obligations of U.S. government agencies $ 14,911 $ (10) $ — $ 14,901 Bank certificates of deposits 6,158 — 3 6,161 U.S. corporate securities 4,749 (1) — 4,748 Municipal securities 3,710 (6) — 3,704 Other debt securities 29 — — 29 $ 29,557 $ (17) $ 3 $ 29,543 September 30, 2017 : Corporate securities $ 2,642 $ — $ — $ 2,642 Other debt securities 28 — — 28 $ 2,670 $ — $ — $ 2,670
Fair Value of Marketable Securities by Contractual Maturity	The fair values of the marketable securities by contractual maturities at December 31, 2017 are presented below (in thousands): Fair Value Due in one year or less $ 15,658 Due after one year through five years 11,148 Due after ten years 2,737 Total marketable securities $ 29,543

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Amounts of Assets and Liabilities at Fair Value as of Acquisition Date	The preliminary amounts recorded were as follows (in thousands): Fair Value of Assets and Liabilities Accounts receivable (approximates contractual value) $ 1,581 Inventories 2,667 Prepaid expenses and other current assets 140 Property, plant and equipment 1,555 Intangible assets 27,212 Goodwill 38,033 Accounts payable (286) Accrued liabilities (624) Deferred tax liabilities (5,090) Total purchase price, net of cash acquired $ 65,188

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Components of Goodwill by Business Segment	The components of the Company’s goodwill by operating segment at December 31, 2017 and September 30, 2017 are as follows (in thousands): Brooks Semiconductor Solutions Brooks Group Life Sciences Other Total Gross goodwill, at September 30, 2017 $ 655,762 $ 166,820 $ 26,014 $ 848,596 Accumulated goodwill impairments (588,944) — (26,014) (614,958) Goodwill, net of accumulated impairments, at September 30, 2017 66,818 166,820 — 233,638 Acquisitions and adjustments (15) 39,101 — 39,086 Gross goodwill, at December 31, 2017 655,747 205,921 26,014 887,682 Accumulated goodwill impairments (588,944) — (26,014) (614,958) Goodwill, net of accumulated impairments, at December 31, 2017 $ 66,803 $ 205,921 $ — $ 272,724
Components of Identifiable Intangible Assets	The components of the Company’s identifiable intangible assets as of December 31, 2017 and September 30, 2017 are as follows (in thousands): December 31, 2017 September 30, 2017 Accumulated Net Book Accumulated Net Book Cost Amortization Value Cost Amortization Value Patents $ 9,028 $ 7,806 $ 1,222 $ 9,028 $ 7,729 $ 1,299 Completed technology 67,032 55,668 11,364 61,662 54,777 6,885 Trademarks and trade names 9,405 5,241 4,164 9,244 4,969 4,275 Customer relationships 152,797 63,790 89,007 130,655 59,594 71,061 $ 238,262 $ 132,505 $ 105,757 $ 210,589 $ 127,069 $ 83,520
Schedule of Future Amortization Expense	Estimated future amortization expense for the intangible assets for the remainder of fiscal year 2018 and the subsequent four fiscal years is as follows (in thousands): Fiscal year ended September 30, 2018 $ 16,454 2019 20,810 2020 19,021 2021 13,240 2022 10,553 Thereafter 25,679 $ 105,757

Debt (Tables)

Debt (Tables)	3 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of Future Minimum Principal Payment Obligations	The following are the future minimum principal payment obligations under the term loan as of December 31, 2017: Amount Fiscal year ended September 30, 2018 $ 1,496 2019 1,978 2020 1,958 2021 1,938 2022 1,919 Thereafter 190,711 Total outstanding principal balance 200,000 Unamortized deferred financing costs (2,731) 197,269 Term loan, current portion 1,993 Term loan, long-term portion $ 195,276

Other Balance Sheet Informati31

Other Balance Sheet Information (Tables)	3 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Accounts Receivable	The following is a summary of accounts receivable at December 31, 2017 and September 30, 201 7 (in thousands): December 31, September 30, 2017 2017 Accounts receivable $ 140,490 $ 122,868 Less allowance for doubtful accounts (1,384) (1,959) Less allowance for sales returns (59) (81) Accounts receivable, net $ 139,047 $ 120,828
Summary of Inventories	The following is a summary of inventories at December 31, 2017 and September 30, 2017 (in thousands): December 31, September 30, 2017 2017 Inventories Raw materials and purchased parts $ 76,389 $ 73,819 Work-in-process 11,729 10,548 Finished goods 26,915 22,028 Total inventories $ 115,033 $ 106,395
Product Warranty and Retrofit Activity on Gross Basis	The following is a summary of product warranty and retrofit activity on a gross basis for the three months ended December 31, 2017 and 2016 (in thousands): Activity -Three Months Ended December 31, 2017 Balance Balance September 30, December 31, 2017 Accruals Costs Incurred 2017 $ 8,054 $ 2,336 $ (2,172) $ 8,218 Activity -Three Months Ended December 31, 2016 Balance Balance September 30, December 31, 2016 Accruals Costs Incurred 2016 $ 6,324 $ 2,507 $ (2,614) $ 6,217

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation Expense	The following table reflects stock-based compensation expense recorded during the three months ended December 31, 2017 and 2016 (in thousands): Three Months Ended December 31, 2017 2016 Restricted stock $ 4,602 $ 2,365 Employee stock purchase plan 207 133 Total stock-based compensation expense $ 4,809 $ 2,498
Restricted Stock Unit Activity	The following table reflects restricted stock units granted during the three months ended December 31, 2017 and 2016: Time-Based Performance- Total Units Units Stock Grants Based Units Three months ended December 31, 2017 471,151 190,266 546 Three months ended December 31, 2016 951,266 362,113 815 The following table summarizes restricted stock unit activity for the three months ended December 31, 2017: Weighted Average Grant-Date Shares Fair Value Outstanding at September 30, 2017 2,474,011 $ 12.34 Granted 471,151 34.25 Vested (586,352) 12.42 Forfeited (14,737) 16.48 Outstanding at December 31, 2017 2,344,073 $ 16.75

Earnings per Share (Tables)

Earnings per Share (Tables)	3 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Reconciliation of Weighted Average Common Shares Outstanding for Purposes of Calculating Basic and Diluted Earnings Per Share	The calculations of basic and diluted net income per share and basic and diluted weighted average shares outstanding are as follows for the three months ended December 31, 2017 and 2016 (in thousands, except per share data): Three Months Ended December 31, 2017 2016 Net income $ 16,486 $ 13,871 Weighted average common shares outstanding used in computing basic earnings per share 70,183 69,181 Dilutive common stock options and restricted stock units 681 689 Weighted average common shares outstanding used in computing diluted earnings per share 70,864 69,870 Basic net income per share $ 0.23 $ Diluted net income per share $ 0.23 $

Restructuring Charges (Tables)

Restructuring Charges (Tables)	3 Months Ended
	Dec. 31, 2017
Restructuring and Related Activities [Abstract]
Activity Related to Restructuring Accruals	The following is a summary of activity related to the Company’s restructuring charges for the three months ended December 31, 2017 and 2016 (in thousands): Activity -Three Months Ended December 31, 2017 Balance Balance September 30, December 31, 2017 Expenses Payments 2017 Total restructuring liabilities related to workforce termination benefits $ 1,708 $ — $ (581) $ 1,127 Activity -Three Months Ended December 31, 2016 Balance Balance September 30, December 31, 2016 Expenses Payments 2016 Total restructuring liabilities related to workforce termination benefits $ 5,939 $ 975 $ (3,687) $ 3,227

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Financial Information for Business Segments	The following is the summary of the financial information for the Company’s operating and reportable segments for the three months ended December 31, 2017 and 2016 (in thousands): Brooks Semiconductor Brooks Solutions Group Life Sciences Total Three Months Ended December 31, 2017: Revenue Products $ 120,203 $ 21,981 $ 142,184 Services 21,683 25,461 47,144 Segment revenue $ 141,886 $ 47,442 $ 189,328 Gross profit $ 59,453 $ 15,762 $ 75,215 Segment operating income (loss) 26,362 (140) 26,222 Depreciation expense 1,149 1,549 2,698 Three Months Ended December 31, 2016: Revenue Products $ 109,395 $ 12,719 $ 122,114 Services 17,221 20,620 37,841 Segment revenue $ 126,616 $ 33,339 $ 159,955 Gross profit $ 45,468 $ 11,475 $ 56,943 Segment operating income (loss) 17,371 112 17,483 Depreciation expense 1,275 1,090 2,365 Assets: December 31, 2017 $ 340,367 $ 382,884 $ 723,251 September 30, 2017 325,408 306,666 632,074
Reconciliation of Reportable Segment Operating Income (Loss) to Corresponding Consolidated Amounts	The following is a reconciliation of the Company’s operating and reportable segments’ operating income and segment assets to the corresponding amounts presented in the accompanying unaudited Consolidated Balance Sheets and Consolidated Statements of Operations for the three months ended December 31, 2017 and 2016 (in thousands): Three Months Ended December 31, 2017 2016 Segment operating income $ 26,222 $ 17,483 Amortization of acquired intangible assets 4,589 3,064 Restructuring charges — 975 Other unallocated corporate expenses 793 283 Total operating income $ 20,840 $ 13,161
Reconciliation of Reportable Segment Assets to Corresponding Consolidated Amounts	December 31, September 30, 2017 2017 Segment assets $ 723,251 $ 632,074 Cash, cash equivalents and marketable securities 231,882 104,292 Deferred tax assets 1,642 1,692 Equity method investments 30,902 28,570 Total assets $ 987,677 $ 766,628

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Foreign Currency Translation (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Foreign Currency Transaction Gain (Loss), before Tax [Abstract]
Foreign currency transaction and remeasurement (losses) gains	$ (2)	$ (0.5)

Summary of Significant Accoun37

Summary of Significant Accounting Policies - Derivative Instruments (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Realized losses on derivative instruments not designated as hedging instruments	$ (1,673)	$ (1,003)

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Fair Value Measurements (Details) - Fair Value, Measurements, Recurring - Significant Unobservable Inputs (Level 3) $ in Thousands	Dec. 31, 2017USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 0
Liabilities measured at fair value	$ 0

Marketable Securities - Summary

Marketable Securities - Summary of Amortized Cost and Fair Value (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Sep. 30, 2017
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 29,557	$ 2,670
Gross Unrealized Losses	(17)
Gross Unrealized Gains	3
Fair Value	29,543	2,670
U.S. Treasury securities and obligations of U.S. government agencies
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	14,911
Gross Unrealized Losses	(10)
Fair Value	14,901
Bank certificates of deposits
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	6,158
Gross Unrealized Gains	3
Fair Value	6,161
Corporate securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	4,749	2,642
Gross Unrealized Losses	(1)
Fair Value	4,748	2,642
Municipal securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	3,710
Gross Unrealized Losses	(6)
Fair Value	3,704
Other debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	29	28
Fair Value	$ 29	$ 28

Marketable Securities - Fair Va

Marketable Securities - Fair Value of Marketable Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Sep. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Due in one year or less	$ 15,658
Due after one year through five years	11,148
Due after ten years	2,737
Fair Value	$ 29,543	$ 2,670

Marketable Securities - Unreali

Marketable Securities - Unrealized Loss Position (Details) - USD ($) $ in Millions	Dec. 31, 2017	Sep. 30, 2017
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Abstract]
Fair value of marketable securities in unrealized loss position	$ 20.3	$ 0

Marketable Securities - Cash Eq

Marketable Securities - Cash Equivalents (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions	Dec. 31, 2017	Sep. 30, 2017
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds
Assets:
Cash equivalents	$ 64.2
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds | Maximum
Assets:
Cash equivalents		$ 0.1
Significant Other Observable Inputs (Level 2)
Assets:
Cash equivalents	$ 9.1
Significant Other Observable Inputs (Level 2) | Maximum
Assets:
Cash equivalents		$ 0.1

Acquisitions - Ownership Inform

Acquisitions - Ownership Information (Details)	Nov. 28, 2016
Cool Lab, LLC
Business Acquisition [Line Items]
Percentage of voting interests acquired (as a percent)	100.00%
BioCision, LLC
Business Acquisition [Line Items]
Equity interest in acquiree, percentage (as a percent)	20.00%

Acquisitions - Purchase Conside

Acquisitions - Purchase Consideration (Details) - USD ($) $ in Thousands	Oct. 05, 2017	Jul. 05, 2017	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Aggregate purchase price, net of cash acquired			$ 65,074	$ 5,346
4titude Limited
Business Acquisition [Line Items]
Aggregate purchase price, net of cash acquired	$ 65,200
Cash payment	64,700
Liabilities incurred	$ 500
PBMMI and Novare
Business Acquisition [Line Items]
Aggregate purchase price, net of cash acquired		$ 34,300

Acquisitions - Amounts of Asset

Acquisitions - Amounts of Assets and Liabilities at Fair Value as of Acquisition Date (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Oct. 05, 2017	Sep. 30, 2017
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill	$ 272,724		$ 233,638
4titude Limited
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Accounts receivable		$ 1,581
Inventories		2,667
Prepaid expenses and other current assets		140
Property, plant and equipment		1,555
Intangible assets		27,212
Goodwill		38,033
Accounts payable		(286)
Accrued liabilities		(624)
Deferred tax liabilities		(5,090)
Total purchase price		$ 65,188

Acquisitions - Intangible Asset

Acquisitions - Intangible Assets Acquired (Details) - 4titude Limited $ in Millions	Oct. 05, 2017USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets (in years)	10 years 4 months 24 days
Customer Relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 21.4
Weighted average useful life of intangible assets (in years)	10 years
Completed Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 5.2
Weighted average useful life of intangible assets (in years)	13 years
Order or Production Backlog
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 0.4
Weighted average useful life of intangible assets (in years)	1 year
Trademarks
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 0.2
Weighted average useful life of intangible assets (in years)	1 year

Acquisitions - Escrow (Details)

Acquisitions - Escrow (Details) - USD ($) $ in Millions	Dec. 31, 2017	Oct. 05, 2017	Jul. 05, 2017
4titude Limited
Business Acquisition [Line Items]
Escrow deposit	$ 0.4	$ 0.4
PBMMI and Novare
Business Acquisition [Line Items]
Escrow deposit			$ 3.3
Escrow deposit for indemnification obligation	2.9		2.9
Escrow deposit for payable to former owner	$ 0.3		$ 0.4

Acquisitions - General Informat

Acquisitions - General Information (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2017	Nov. 28, 2016
Business Acquisition [Line Items]
Amortization of acquired intangible assets	$ 5.5	$ 4.1
4titude Limited
Business Acquisition [Line Items]
Actual revenues	3.4
Actual net income (loss)	(1.1)
Inventory step up	1.2
Amortization of acquired intangible assets	1
PBMMI and Novare
Business Acquisition [Line Items]
Actual revenues	2.3
Actual net income (loss)	(0.1)
Amortization of acquired intangible assets	0.4
Cool Lab, LLC
Business Acquisition [Line Items]
Liabilities arising from contingencies, amount recognized	0.8		$ 0.7	$ 0.7
Actual revenues	1	0.3
Actual net income (loss)		(0.1)
Amortization of acquired intangible assets	0.4	$ 0.1
Selling, General and Administrative Expenses | 4titude Limited
Business Acquisition [Line Items]
Acquisition related costs	0.5
Maximum | Cool Lab, LLC
Business Acquisition [Line Items]
Actual net income (loss)	$ (0.1)

Goodwill and Intangible Asset49

Goodwill and Intangible Assets - Components of Goodwill by Operating Segment (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Sep. 30, 2017
Goodwill [Line Items]
Gross goodwill	$ 887,682	$ 848,596
Accumulated goodwill impairments	(614,958)	(614,958)
Goodwill	272,724	233,638
Brooks Semiconductor Solutions Group
Goodwill [Line Items]
Gross goodwill	655,747	655,762
Accumulated goodwill impairments	(588,944)	(588,944)
Goodwill	66,803	66,818
Brooks Life Science Systems
Goodwill [Line Items]
Gross goodwill	205,921	166,820
Goodwill	205,921	166,820
Other
Goodwill [Line Items]
Gross goodwill	26,014	26,014
Accumulated goodwill impairments	$ (26,014)	$ (26,014)

Goodwill and Intangible Asset50

Goodwill and Intangible Assets - Goodwill Roll Forward (Details) $ in Thousands	3 Months Ended
	Dec. 31, 2017USD ($)
Goodwill [Roll Forward]
Goodwill, net of accumulated impairments, beginning balance	$ 233,638
Acquisitions and adjustments	39,086
Goodwill, net of accumulated impairments, ending balance	272,724
Brooks Semiconductor Solutions Group
Goodwill [Roll Forward]
Goodwill, net of accumulated impairments, beginning balance	66,818
Acquisitions and adjustments	(15)
Goodwill, net of accumulated impairments, ending balance	66,803
Brooks Life Science Systems
Goodwill [Roll Forward]
Goodwill, net of accumulated impairments, beginning balance	166,820
Acquisitions and adjustments	39,101
Goodwill, net of accumulated impairments, ending balance	$ 205,921

Goodwill and Intangible Asset51

Goodwill and Intangible Assets - Goodwill Acquired (Details) $ in Millions	3 Months Ended
	Dec. 31, 2017USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill acquired during period	$ 39.1

Goodwill and Intangible Asset52

Goodwill and Intangible Assets - Components of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Sep. 30, 2017
Finite-Lived Intangible Assets [Line Items]
Cost	$ 238,262	$ 210,589
Accumulated Amortization	132,505	127,069
Net Book Value	105,757	83,520
Patents
Finite-Lived Intangible Assets [Line Items]
Cost	9,028	9,028
Accumulated Amortization	7,806	7,729
Net Book Value	1,222	1,299
Completed Technology
Finite-Lived Intangible Assets [Line Items]
Cost	67,032	61,662
Accumulated Amortization	55,668	54,777
Net Book Value	11,364	6,885
Trademarks and Trade Names
Finite-Lived Intangible Assets [Line Items]
Cost	9,405	9,244
Accumulated Amortization	5,241	4,969
Net Book Value	4,164	4,275
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Cost	152,797	130,655
Accumulated Amortization	63,790	59,594
Net Book Value	$ 89,007	$ 71,061

Goodwill and Intangible Asset53

Goodwill and Intangible Assets - Amortization Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense for intangible assets	$ 5.5	$ 4.1

Goodwill and Intangible Asset54

Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Sep. 30, 2017
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2,018	$ 16,454
2,019	20,810
2,020	19,021
2,021	13,240
2,022	10,553
Thereafter	25,679
Net Book Value	$ 105,757	$ 83,520

Equity Method Investments (Deta

Equity Method Investments (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2017
Schedule of Equity Method Investments [Line Items]
Equity method investment	$ 30,925		$ 28,593
Equity in earnings of equity method investment	$ 2,180	$ 1,942
ULVAC Cryogenics, Inc.
Schedule of Equity Method Investments [Line Items]
Joint venture interest (as a percent)	50.00%
Equity method investment	$ 30,900		$ 28,600
Equity in earnings of equity method investment	2,200	2,400
Management fee payments received	$ 300	$ 300

Line of Credit (Details)

Line of Credit (Details) - USD ($) $ in Millions	Dec. 31, 2017	Oct. 04, 2017	Sep. 30, 2017
Credit Agreement | Line of Credit
Line of Credit Facility [Line Items]
Outstanding line of credit	$ 0		$ 0
Deferred finance costs	0.6		$ 0.5
Credit Agreement | Line of Credit | Revolving Credit Facility
Line of Credit Facility [Line Items]
Line of credit, maximum borrowing capacity	$ 75	$ 75
Credit Agreement | Line of Credit | Letter of Credit
Line of Credit Facility [Line Items]
Line of credit, maximum borrowing capacity		7.5
Senior Secured Term Loan Facility | Secured Debt
Line of Credit Facility [Line Items]
Face amount		$ 200

Debt - General Information (Det

Debt - General Information (Details) $ in Thousands	Dec. 31, 2017USD ($)	Oct. 04, 2017USD ($)
Debt Instrument [Line Items]
Long-term debt	$ 197,269
Senior Secured Term Loan Facility | Secured Debt
Debt Instrument [Line Items]
Face amount		$ 200,000
Long-term debt		$ 197,600
Percentage of par (as a percent)		98.80%
Discount		$ 2,400
Discount percentage (as a percent)		1.20%
Deferred financing costs	$ 400
Aggregate increase amount		$ 75,000
Maximum secured leverage ratio		3

Debt - Interest Rate (Details)

Debt - Interest Rate (Details) - Secured Debt - Senior Secured Term Loan Facility	Oct. 04, 2017
Eurodollar
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as a percent)	2.50%
Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as a percent)	1.50%
Federal Funds Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as a percent)	0.50%
Prime Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as a percent)	1.00%
London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as a percent)	1.00%

Debt - Payment Terms (Details)

Debt - Payment Terms (Details) - Senior Secured Term Loan Facility - Secured Debt	Oct. 04, 2017
Debt Instrument [Line Items]
Installment payment percentage (as a percent)	0.25%
Premium percentage during first six months of loan term (as a percent)	1.00%
Prepayment percentage (as a percent)	50.00%

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2017	Oct. 04, 2017
Debt Instrument [Line Items]
Deferred financing costs	$ 2,731
Senior Secured Term Loan Facility | Secured Debt
Debt Instrument [Line Items]
Deferred financing costs	$ 2,700
Weighted average interest rate (as a percent)	4.00%
Interest expense	$ 2,100
Deferred financing costs amortization	$ 100
Interest rate above applicable rate (as a percent)		2.00%

Debt - Future Minimum Principal

Debt - Future Minimum Principal Payment Obligations (Details) $ in Thousands	Dec. 31, 2017USD ($)
Long-term Debt, Fiscal Year Maturity [Abstract]
2,018	$ 1,496
2,019	1,978
2,020	1,958
2,021	1,938
2,022	1,919
Thereafter	190,711
Total outstanding principal balance	200,000
Unamortized deferred financing costs	(2,731)
Long-term debt	$ 197,269

Debt - Current and Non-current

Debt - Current and Non-current (Details) $ in Thousands	Dec. 31, 2017USD ($)
Long-term Debt, by Current and Noncurrent [Abstract]
Long-term debt	$ 197,269
Term loan, current portion	1,993
Term loan, long-term portion	$ 195,276

Income Taxes - Provision (Detai

Income Taxes - Provision (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Expense (Benefit), Continuing Operations [Abstract]
Income tax provision	$ 2,850	$ 2,800

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Reductions in unrecognized tax benefits from expiration	$ 0.3	$ 0.7
Benefit related to re-measurement of deferred tax liabilities	$ 0.7
U.S. statutory federal tax rate (as a percent)	35.00%		21.00%
Cumulative effect adjustment to retained earnings	$ 4
Toll charge, payable period	8 years
Toll charge, estimated foreign earnings	$ 120
U.S. statutory federal tax rate, prorated allocation (as a percent)	24.50%
Anticipated unrecognized tax benefit reduction during next twelve months	$ 0.2

Other Balance Sheet Informati65

Other Balance Sheet Information - Summary of Account Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Sep. 30, 2017
Valuation and Qualifying Accounts Disclosure [Line Items]
Accounts receivable	$ 140,490	$ 122,868
Less allowance for doubtful accounts	(1,384)	(1,959)
Accounts receivable, net	139,047	120,828
Allowance for Sales Returns
Valuation and Qualifying Accounts Disclosure [Line Items]
Less allowance for sales returns	$ (59)	$ (81)

Other Balance Sheet Informati66

Other Balance Sheet Information - Summary of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials and purchased parts	$ 76,389	$ 73,819
Work-in-process	11,729	10,548
Finished goods	26,915	22,028
Inventory, net	115,033	106,395
Reserves for excess and obsolete inventory	$ 22,900	$ 23,500

Other Balance Sheet Informati67

Other Balance Sheet Information - Capitalized Direct Costs (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2017	Sep. 30, 2017
Property, Plant and Equipment, Gross [Abstract]
Capitalized computer software, gross	$ 5	$ 4.7
Capitalized computer software costs	$ 0.3

Other Balance Sheet Informati68

Other Balance Sheet Information - Product Warranty and Retrofit Activity on Gross Basis (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Beginning Balance	$ 8,054	$ 6,324
Accruals for warranties	2,336	2,507
Costs incurred	(2,172)	(2,614)
Ending Balance	$ 8,218	$ 6,217

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 4,809	$ 2,498
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	4,602	2,365
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 207	$ 133

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units Granted (Details) - shares	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	471,151	951,266
Restricted Stock, Time Based Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	190,266	362,113
Board of Director Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	546	815
Restricted Stock, Performance Based Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	280,339	588,338

Stock-Based Compensation - Time

Stock-Based Compensation - Time-Based Grants (Details) - Restricted Stock, Time Based Shares	3 Months Ended
	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Share-based Compensation Award, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage (as a percent)	33.33%
Share-based Compensation Award, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage (as a percent)	33.33%
Share-based Compensation Award, Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage (as a percent)	33.33%

Stock-Based Compensation - St72

Stock-Based Compensation - Stock Grants (Details) - shares	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Board of Director Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	546	815
Board of Director Units, Deferred Quarterly Dividends
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	546	815
Board of Director Units, Deferred Annual Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	0	0
Board of Director Units, Compensation Related Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	0	0

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance-Based Grants (Details) - Restricted Stock, Performance Based Shares	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance-based awards granted, percentage, minimum (as a percent)		0.00%
Performance-based awards granted, percentage (as a percent)	100.00%	100.00%
Performance-based awards granted, percentage, maximum threshold met (as a percent)	200.00%	200.00%
Performance goal measurement period (in years)	3 years

Stock-Based Compensation - Re74

Stock-Based Compensation - Restricted Stock Unit Activity - Tabular Disclosure (Details) - Restricted Stock Units (RSUs) - $ / shares	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Shares
Outstanding at beginning of period (in shares)	2,474,011
Granted (in shares)	471,151	951,266
Vested (in shares)	(586,352)
Forfeited (in shares)	(14,737)
Outstanding at end of period (in shares)	2,344,073
Weighted Average Grant-Date Fair Value
Outstanding at beginning of period (in dollars per share)	$ 12.34
Granted (in dollars per share)	34.25	$ 13.93
Vested (in dollars per share)	12.42
Forfeited (in dollars per share)	16.48
Outstanding at end of period (in dollars per share)	$ 16.75

Stock-Based Compensation - Re75

Stock-Based Compensation - Restricted Stock Unit Activity - Additional Information (Details) - Restricted Stock Units (RSUs) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in dollars per share)	$ 34.25	$ 13.93
Fair value of restricted stock awards vested	$ 19	$ 11.3
Withholding taxes remitted	6.3	3.8
Withholding taxes paid	0	0.1
Proceeds from employees to satisfy tax obligation	$ 6.3	$ 3.7

Stock-Based Compensation - Re76

Stock-Based Compensation - Restricted Stock Unit Activity - Unrecognized Compensation Cost (Details) - Restricted Stock Units (RSUs) $ in Millions	3 Months Ended
	Dec. 31, 2017USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 33.2
Unrecognized compensation cost, estimated weighted average amortization period	1 year 10 months 24 days

Stock-Based Compensation - Empl

Stock-Based Compensation - Employee Stock Purchase Plan (Details) - shares	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued under employee stock purchase plan (in shares)	0	0
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock (as a percent)	85.00%

Earnings per Share - Tabular Di

Earnings per Share - Tabular Disclosure (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Earnings Per Share [Abstract]
Net income (loss)	$ 16,486	$ 13,871
Weighted average common shares outstanding used in computing basic earnings (losses) per share (in shares)	70,183	69,181
Dilutive common stock options and restricted stock units (in shares)	681	689
Weighted average common shares outstanding used in computing diluted earnings (losses) per share (in shares)	70,864	69,870
Basic net income (loss) per share (in dollars per share)	$ 0.23	$ 0.20
Diluted net income per share (in dollars per share)	$ 0.23	$ 0.20

Earnings per Share - Anti-dilut

Earnings per Share - Anti-dilutive Securities (Details) - shares	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted earnings per share (in shares)	190,000	0

Restructuring Charges - General

Restructuring Charges - General Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2017	Sep. 30, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 975
Accrued restructuring costs		$ 1,127	$ 1,708
Workforce-related termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	975
Streamline Service Operations, Initiated Fiscal Year 2017 | Brooks Semiconductor Solutions Group | Workforce-related termination benefits
Restructuring Cost and Reserve [Line Items]
Accrued restructuring costs		200
Reduce Global Footprint and Streamline Cost Structure, Initiated Fiscal Year 2016 | Brooks Semiconductor Solutions Group | Workforce-related termination benefits
Restructuring Cost and Reserve [Line Items]
Accrued restructuring costs		$ 800
Integration of Contact Acquisition Initiated in Fiscal Year 2016 | Brooks Semiconductor Solutions Group | Workforce-related termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	200
Streamlining Segment Structure, Integrating Acquisition, and Facility Closure, Initiated in Fiscal Year 2016 | Brooks Life Science Systems | Workforce-related termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	100
Company-wide Action Initiated in Fiscal Year 2016 | Workforce-related termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 700

Restructuring Charges - Activit

Restructuring Charges - Activity Related to Restructuring Accruals (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Restructuring Reserve [Roll Forward]
Expenses		$ 975
Workforce-related termination benefits
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 1,708	5,939
Expenses		975
Payments	(581)	(3,687)
Ending Balance	$ 1,127	$ 3,227

Segment Information - General I

Segment Information - General Information (Details) - segment	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Segment Reporting [Abstract]
Number of operating segments	2	2
Number of reportable segments	2	2

Segment Information - Financial

Segment Information - Financial Information for Business Segments (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2017
Revenue
Products	$ 142,184	$ 122,114
Services	47,144	37,841
Total revenue	189,328	159,955
Gross profit	75,215	56,943
Segment operating income (loss)	20,840	13,161
Total assets	987,677		$ 766,628
Brooks Semiconductor Solutions Group
Revenue
Products	120,203	109,395
Services	21,683	17,221
Total revenue	141,886	126,616
Gross profit	59,453	45,468
Brooks Life Science Systems
Revenue
Products	21,981	12,719
Services	25,461	20,620
Total revenue	47,442	33,339
Gross profit	15,762	11,475
Operating Segments
Revenue
Segment operating income (loss)	26,222	17,483
Depreciation expense	2,698	2,365
Total assets	723,251		632,074
Operating Segments | Brooks Semiconductor Solutions Group
Revenue
Segment operating income (loss)	26,362	17,371
Depreciation expense	1,149	1,275
Total assets	340,367		325,408
Operating Segments | Brooks Life Science Systems
Revenue
Segment operating income (loss)	(140)	112
Depreciation expense	1,549	$ 1,090
Total assets	$ 382,884		$ 306,666

Segment Information - Reconcili

Segment Information - Reconciliation of Reportable Segment Operating Income (Loss) to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Amortization of acquired intangible assets	$ 5,500	$ 4,100
Restructuring Charges		975
Total operating income (loss)	20,840	13,161
Operating Segments
Segment Reporting Information [Line Items]
Total operating income (loss)	26,222	17,483
Segment Reconciling Items
Segment Reporting Information [Line Items]
Amortization of acquired intangible assets	4,589	3,064
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Other unallocated corporate expenses	$ 793	$ 283

Segment Information - Reconci85

Segment Information - Reconciliation of Reportable Segment Assets to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Sep. 30, 2017
Segment Reporting Information [Line Items]
Assets	$ 987,677	$ 766,628
Cash, cash equivalents and marketable securities	231,882	104,292
Deferred tax assets	1,642	1,692
Equity method investment	30,925	28,593
Operating Segments
Segment Reporting Information [Line Items]
Assets	723,251	632,074
Segment Reconciling Items
Segment Reporting Information [Line Items]
Equity method investment	$ 30,902	$ 28,570

Significant Customers (Details)

Significant Customers (Details) - Customer Concentration Risk - Sales Revenue, Net	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fiscal Year 2018, First Quarter, Major Customer, Consolidated Revenue [Member]
Concentration Risk [Line Items]
Concentration risk, percentage (as a percent)	11.00%
Fiscal Year 2017, First Quarter, Major Customer, Consolidated Revenue [Member]
Concentration Risk [Line Items]
Concentration risk, percentage (as a percent)		11.00%

Commitments and Contingencies -

Commitments and Contingencies - Letters of Credit (Details) - USD ($) $ in Millions	Dec. 31, 2017	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Outstanding letters of credit	$ 3.5	$ 3.5

Commitments and Contingencies88

Commitments and Contingencies - Purchase Commitments (Details) - USD ($) $ in Millions	Dec. 31, 2017	Sep. 30, 2017
Non-cancellable Contracts and Purchase Orders for Inventory
Other Commitments [Line Items]
Other Commitment	$ 128.6	$ 122

Subsequent Events (Details)

Subsequent Events (Details) - $ / shares	Jan. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Cash dividend declared (in dollars per share)		$ 0.10	$ 0.10
Subsequent Event
Subsequent Event [Line Items]
Cash dividend declared (in dollars per share)	$ 0.10
Cash dividend declared, payment date	Mar. 23, 2018
Cash dividend declared, record date	Mar. 2, 2018